[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366264-105":59,"doc-detail-366264-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","harnessing-organoid-platforms-for-nanoparticle-drug-development-open-access-full-text-article-review","Harnessing Organoid Platforms for Nanoparticle Drug Development - Open Access Full Text Article REVIEW","","Cancer nanomedicine offers transformative potential, yet clinical translation is delayed by preclinical models that cannot faithfully represent human tumor complexity. Conventional systems often ignore the dynamic tumor microenvironment (TME) and interpatient variability, producing unreliable forecasts of nanoparticle drug behavior. Tumor organoids provide three-dimensional cultures preserving tumor architecture, molecular profiles, and TME interactions, enabling evaluation of delivery efficiency, therapeutic efficacy, and safety across pancreatic, breast, and glioblastoma cancers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-organoid-platforms-for-nanoparticle-drug-development-open-access-full-text-article-review/366264/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-organoid-platforms-for-nanoparticle-drug-development-open-access-full-text-article-review/366264.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are conventional preclinical models inadequate for nanoparticle drug translation?","Question",{"text":113,"@type":114},"They often fail to mimic human tumor complexity, particularly the dynamic tumor microenvironment and interpatient variability, leading to unreliable predictions of nanodrug behavior.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What advantages do tumor organoids provide for nanoparticle evaluation?",{"text":118,"@type":114},"Organoids retain the original tumor’s architecture, molecular profiles, and TME interactions, enabling more dependable assessment of delivery, therapeutic effects, and safety.",{"name":120,"@type":111,"acceptedAnswer":121},"How do organoids differ from spheroids in this context?",{"text":122,"@type":114},"Spheroids are simplified 3D aggregates that lack heterogeneity, whereas organoids have higher biological relevance and broader applicability for evaluating nanoparticle responses.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366264,1790463072,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Drug Design, Development and Therapy  \nOpen Access Full Text Article REVIEW  \nHarnessing Organoid Platforms for Nanoparticle Drug Development  \nLinanni Chen 1–4 , *, Xinying Luo 1–4 , *, Jiankang Zhang 1–4 , Jinwen Zhang 1–4 , Chunting Yang 1–4 , Yunqi Zhao 1–4  \n1College of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, Zhejiang, People’s Republic of China; 2Wenzhou Municipal Key Laboratory for Applied Biomedical and Biopharmaceutical Informatics, Wenzhou-Kean University, Wenzhou, Zhejiang, People’s Republic of China; 3Zhejiang Bioinformatics International Science and Technology Cooperation Center, Wenzhou-Kean University, Wenzhou, Zhejiang, People’s Republic of China; 4Dorothy and George Hennings College of Science, Mathematics and Technology, Kean University, Union, NJ, USA  \n*These authors contributed equally to this work  \nCorrespondence: Yunqi Zhao, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 Daxue Road, Wenzhou, Zhejiang, 325060, People’s Republic of China, [Email yuzhao@kean.edu](Email yuzhao@kean.edu)  \n\n| Abstract: Cancer nanomedicine holds transformative potential, but its clinical translation remains hindered by the lack of preclinical models that accurately mimic human tumor complexity. Conventional approaches often overlook the dynamic tumor microenvironment (TME) and interpatient variability, leading to unreliable predictions of nanodrug behavior. Here, we present tumor organoids asa transformative solution. These three-dimensional cultures retain the original tumor’s architecture, molecular profiles, and TME interactions. Through concrete examples spanning pancreatic, breast, and glioblastoma cancers, we showcase how organoids reliably evaluate nanodrug delivery efficiency, therapeutic effects, and safety profiles. In addition, the establishment of large-scale organoid biobanks further facilitates rapid drug screening and tailored treatment strategies, significantly improving preclinical success rates. Therefore, the organoid-driven paradigm not only overcomes long-standing challenges in tumor modeling but also paves a faster, more reliable path toward clinically effective nanotherapies.\u003Cbr>Keywords: cancer, drug screening, nanoparticle, organoid, personalized medicine |\n| --- |\n| Introduction\u003Cbr>The advent of nanotechnology has heralded a new era in the field of cancer treatment, with nanoparticles emerging as promising candidates for improving efficacy and reducing side effects.1 Despite the promise of nanoparticles in preclinical studies, translating these nanoscale drug delivery systems into clinical practice has been slow. Accurately evaluating the safety and efficacy of nanomedicine in preclinical studies is still a challenge. The complexity of the tumor microenvironment (TME) can impede the penetration and uptake of nanomedicines and influence tumor progression and metastasis. It also plays a crucial role in determining the therapeutic response.2 Therefore, there is a critical need for more representative and predictive models that can accurately mimic human tumor pathophysiology to predict drug responses.\u003Cbr>Traditional two-dimensional (2D) monolayer cultures have served as the foundation of cancer research for decades, with tumor cells typically grown as flat sheets on artificial surfaces. However, researchers now recognize that these systems cannot reproduce the intricate three-dimensional structure and cellular diversity found in actual human tumors.3 Unlike living tumors, these simplified models lack essential biological features, including proper cell-to-cell communication, extracellular matrix networks, and the spatial organization that collectively determine how nanoparticles behave in real tissue. In this context, spheroids emerge as a cost-effective option for preliminary screening, similar to 2D models.4 While both organoids and spheroids serve as 3D models for nanoparticle evaluation, they exhibit fundamental differences in biological re","cbCailZv0XcIbokV","https://ap.wps.com/l/cbCailZv0XcIbokV","pdf",3400115,"English","# Introduction\n## Limitations of 2D monolayer cultures\n## Spheroids as a preliminary 3D option\n## Differences between organoids and spheroids","[{\"question\":\"Why are conventional preclinical models inadequate for nanoparticle drug translation?\",\"answer\":\"They often fail to mimic human tumor complexity, particularly the dynamic tumor microenvironment and interpatient variability, leading to unreliable predictions of nanodrug behavior.\"},{\"question\":\"What advantages do tumor organoids provide for nanoparticle evaluation?\",\"answer\":\"Organoids retain the original tumor’s architecture, molecular profiles, and TME interactions, enabling more dependable assessment of delivery, therapeutic effects, and safety.\"},{\"question\":\"How do organoids differ from spheroids in this context?\",\"answer\":\"Spheroids are simplified 3D aggregates that lack heterogeneity, whereas organoids have higher biological relevance and broader applicability for evaluating nanoparticle responses.\"}]","Harnessing Organoid Platforms for Nanoparticle Drug Development - Open Access Full Text Article REVIEW | PDF",1790164472,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/015bed16e66e54f166f303a1b33444f4.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a29b88ed509786e21a9ae6d22dc0398.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14792fd4d91c1cc52b71a59a490e8dbe.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e86a648dca43d3f290e08625a363fb44.webp",980,1268]